Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
复制标题
DOI：
10.1136/annrheumdis-2015-209057
复制
发表时间：
2017-01-01
影响因子：
27.4
通讯作者：
Weinblatt, M. E.
中科院分区：
文献类型：
--
作者：
Emery, P.;Bingham, C. O., III;Weinblatt, M. E.
目的：评估certolizumab pegol (CZP)+剂量优化的甲氨蝶呤（MTX）与安慰剂(PBO)+剂量优化的MTX在诱导和维持中度至重度活动性进行性类风湿性关节炎（RA）的dmard初始患者临床缓解的有效性和安全性，预后不良因素超过52周。方法
Objectives To assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naive patients with moderate-to-severe, active, progressive rheumatoid arthritis (RA), with poor prognostic factors over 52 weeks.Methods DMARD-naive patients with